Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil Combined with Immunotherapy in mCRPC
NCT07250542Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fasudil in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: PSA level at 4 months. Started Jul 2024; status: recruiting.
02
Drugs
fasudil
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07250542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250542.